FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2123676976> ?p ?o ?g. }

• W2123676976 endingPage "16" @default.
• W2123676976 startingPage "16" @default.
• W2123676976 abstract "The symptomatic drugs currently on the market for Alzheimer’s disease (AD) have no effect on disease progression, and this creates a large unmet medical need. The type of drug that has developed most rapidly in the last decade is immunotherapy: vaccines and, especially, passive vaccination with monoclonal antibodies. Antibodies are attractive drugs as they can be made highly specific for their target and often with few side effects. Data from recent clinical AD trials indicate that a treatment effect by immunotherapy is possible, providing hope for a new generation of drugs. The first anti-amyloid-beta (anti-Aβ) vaccine developed by Elan, AN1792, was halted in phase 2 because of aseptic meningoencephalitis. However, in a follow-up study, patients with antibody response to the vaccine demonstrated reduced cognitive decline, supporting the hypothesis that Aβ immunotherapy may have clinically relevant effects. Bapineuzumab (Elan/Pfizer Inc./Johnson & Johnson), a monoclonal antibody targeting fibrillar Aβ, was stopped because the desired clinical effect was not seen. Solanezumab (Eli Lilly and Company) was developed to target soluble, monomeric Aβ. In two phase 3 studies, Solanezumab did not meet primary endpoints. When data from the two studies were pooled, a positive pattern emerged, revealing a significant slowing of cognitive decline in the subgroup of mild AD. The Arctic mutation has been shown to specifically increase the formation of soluble Aβ protofibrils, an Aβ species shown to be toxic to neurons and likely to be present in all cases of AD. A monoclonal antibody, mAb158, was developed to target Aβ protofibrils with high selectivity. It has at least a 1,000-fold higher selectivity for protofibrils as compared with monomers of Aβ, thus targeting the toxic species of the peptide. A humanized version of mAb158, BAN2401, has now entered a clinical phase 2b trial in a collaboration between BioArctic Neuroscience and Eisai without the safety concerns seen in previous phase 1 and 2a trials. Experiences from the field indicate the importance of initiating treatment early in the course of the disease and of enriching the trial population by improving the diagnostic accuracy. BAN2401 is a promising candidate for Aβ immunotherapy in early AD. Other encouraging efforts in immunotherapy as well as in the small-molecule field offer hope for new innovative therapies for AD in the future." @default.
• W2123676976 created "2016-06-24" @default.
• W2123676976 creator A5001885896 @default.
• W2123676976 creator A5018345023 @default.
• W2123676976 creator A5029246780 @default.
• W2123676976 creator A5030800916 @default.
• W2123676976 creator A5048990326 @default.
• W2123676976 creator A5049494615 @default.
• W2123676976 creator A5055348919 @default.
• W2123676976 creator A5091668634 @default.
• W2123676976 date "2014-01-01" @default.
• W2123676976 modified "2023-10-16" @default.
• W2123676976 title "Perspectives on future Alzheimer therapies: amyloid-β protofibrils - a new target for immunotherapy with BAN2401 in Alzheimer’s disease" @default.
• W2123676976 cites W1540282518 @default.
• W2123676976 cites W1553423283 @default.
• W2123676976 cites W1616122655 @default.
• W2123676976 cites W188237391 @default.
• W2123676976 cites W1979590358 @default.
• W2123676976 cites W1985030911 @default.
• W2123676976 cites W1990752558 @default.
• W2123676976 cites W1990975951 @default.
• W2123676976 cites W1993571512 @default.
• W2123676976 cites W1993780955 @default.
• W2123676976 cites W1996216953 @default.
• W2123676976 cites W2000706612 @default.
• W2123676976 cites W2000917982 @default.
• W2123676976 cites W2001436176 @default.
• W2123676976 cites W2004535959 @default.
• W2123676976 cites W2006696380 @default.
• W2123676976 cites W2011402798 @default.
• W2123676976 cites W2015675204 @default.
• W2123676976 cites W2029695041 @default.
• W2123676976 cites W2030641075 @default.
• W2123676976 cites W2036963269 @default.
• W2123676976 cites W2040863516 @default.
• W2123676976 cites W2051651977 @default.
• W2123676976 cites W2052226124 @default.
• W2123676976 cites W2053488262 @default.
• W2123676976 cites W2063808031 @default.
• W2123676976 cites W2075481535 @default.
• W2123676976 cites W2078992020 @default.
• W2123676976 cites W2080592458 @default.
• W2123676976 cites W2081569845 @default.
• W2123676976 cites W2087924155 @default.
• W2123676976 cites W2090150925 @default.
• W2123676976 cites W2094411486 @default.
• W2123676976 cites W2096410114 @default.
• W2123676976 cites W2100610042 @default.
• W2123676976 cites W2101077392 @default.
• W2123676976 cites W2118935254 @default.
• W2123676976 cites W2119197968 @default.
• W2123676976 cites W2131303491 @default.
• W2123676976 cites W2150231759 @default.
• W2123676976 cites W2152222652 @default.
• W2123676976 cites W2154755614 @default.
• W2123676976 cites W2157064933 @default.
• W2123676976 cites W2167840686 @default.
• W2123676976 cites W4244678912 @default.
• W2123676976 doi "https://doi.org/10.1186/alzrt246" @default.
• W2123676976 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4054967" @default.
• W2123676976 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25031633" @default.
• W2123676976 hasPublicationYear "2014" @default.
• W2123676976 type Work @default.
• W2123676976 sameAs 2123676976 @default.
• W2123676976 citedByCount "116" @default.
• W2123676976 countsByYear W21236769762014 @default.
• W2123676976 countsByYear W21236769762015 @default.
• W2123676976 countsByYear W21236769762016 @default.
• W2123676976 countsByYear W21236769762017 @default.
• W2123676976 countsByYear W21236769762018 @default.
• W2123676976 countsByYear W21236769762019 @default.
• W2123676976 countsByYear W21236769762020 @default.
• W2123676976 countsByYear W21236769762021 @default.
• W2123676976 countsByYear W21236769762022 @default.
• W2123676976 countsByYear W21236769762023 @default.
• W2123676976 crossrefType "journal-article" @default.
• W2123676976 hasAuthorship W2123676976A5001885896 @default.
• W2123676976 hasAuthorship W2123676976A5018345023 @default.
• W2123676976 hasAuthorship W2123676976A5029246780 @default.
• W2123676976 hasAuthorship W2123676976A5030800916 @default.
• W2123676976 hasAuthorship W2123676976A5048990326 @default.
• W2123676976 hasAuthorship W2123676976A5049494615 @default.
• W2123676976 hasAuthorship W2123676976A5055348919 @default.
• W2123676976 hasAuthorship W2123676976A5091668634 @default.
• W2123676976 hasBestOaLocation W21236769761 @default.
• W2123676976 hasConcept C126322002 @default.
• W2123676976 hasConcept C143998085 @default.
• W2123676976 hasConcept C159654299 @default.
• W2123676976 hasConcept C203014093 @default.
• W2123676976 hasConcept C22070199 @default.
• W2123676976 hasConcept C2777701055 @default.
• W2123676976 hasConcept C2779134260 @default.
• W2123676976 hasConcept C2779483572 @default.
• W2123676976 hasConcept C2984863031 @default.
• W2123676976 hasConcept C535046627 @default.
• W2123676976 hasConcept C542903549 @default.
• W2123676976 hasConcept C71924100 @default.
• W2123676976 hasConcept C8891405 @default.

• next